HIGHLIGHTS
- who: Heli Tolppanen from the Heart Center, Päijät-Häme Central Hospital, Lahti, Finland have published the research: Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock, in the Journal: (JOURNAL)
- what: The aim of the study was to evaluate the prognostic value and association with hemodynamic parameters of bioactive adrenomedullin (bio-ADM) in patients with CS. This study shows that bio-ADM has strong prognostic value in CS when measured after the initial phase of management (at 48 h or later), and is associated with impaired hemodynamics . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.